clinical trial · NCT06246149
Adjuvant Tebentafusp in High Risk Ocular Melanoma
European Organisation for Research and Treatment of Cancer - EORTC·phase3·recruiting·n = 290
Uveal MelanomaTebentafusp
brief summary
At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastatic uveal melanoma in a randomized trial. Based on the results in the advanced setting, it is hypothesized that treatment with tebentafusp may reduce the risk of development of disease recurrence.
started
Nov 11, 2024
primary completion
Nov 1, 2032
completion
Nov 1, 2032
last updated
Mar 4, 2026
official title
Adjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*02:01 Positive Patients Following Definitive Treatment of High-risk Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol